Company Profile:

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons and arthroscopic enabling technologies for healthcare providers. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures. In addition, the company offers advanced wound care products for the treatment of acute and chronic wounds, and biologics and other bioactive technology products for debridement and dermal repair/regeneration. It primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

Recent News:

For the half-year ended June 30, 2017. the company reported evenues of USD 2,194.07 million, Net Earnings of USD 304.31 million.

On Feb. 22, 2017, the company has taken a strategic investment and signed a distribution agreement with Leaf Healthcare, a developer of a unique wireless patient monitoring system for pressure ulcer/injury prevention.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

SNN’s strengths can be seen in its better growth, strong profitability, better solvency and better efficiency compared with its peers. Its revenue has increased over several years. Technical indicators signal the bullish signs, as there is a bullish cross in Stochastic Oscillator and RSI (14) stands at 55.64 with positive bias. We rate Smith & Nephew plc (SNN) a STRONG BUY.